+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and patient-reported outcomes of a port delivery system PDS implant delivering ranibizumab for people with neovascular age-related macular degeneration nAMD. This study focuses on a 36-week refill schedule for the PDS implant filled with ranibizumab 100 mgmL. Participants include adults aged 50 and older with recent nAMD diagnosis and prior anti-VEGF treatment response. Participants will have the PDS implant surgically inserted in the study eye, containing approximately a 2-mg dose of ranibizumab. Based on disease activity at Week 24 or use of supplemental ranibizumab injections before Week 24, participants will receive implant refill exchanges every 24 weeks or every 36 weeks if disease activity criteria are not met. Supplemental intravitreal ranibizumab injections may be given as needed. During the study, participants will undergo regular assessments including visual acuity tests using the ETDRS chart and optical coherence tomography OCT imaging to monitor eye health and treatment effects. The study will track visual acuity changes, supplemental treatments, adverse events, and patient preferences over approximately 72 weeks. Safety and device-related events will be monitored up to around 19 months. The total participation duration aligns with the study completion date in 2028.

Age: 50Years +All GendersPhase 3
61 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
R

Actively Recruiting

Neovascular age-related macular degeneration nAMD, often called wet AMD, involves abnormal growth of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. This research aims to evaluate the safety and effectiveness of Surabgene Lomparvovec, an investigational gene therapy, in adults aged 50 and older who have been previously treated for nAMD. Approximately 561 participants will be enrolled globally and randomized into three groups to compare different treatments. Participants will be assigned to one of three groups two groups receive a single subretinal injection of Surabgene Lomparvovec at different doses, and the third group receives Ranibizumab injections as needed throughout the study. Ranibizumab is given as an intravitreal injection into the jelly-like tissue inside the eye, while Surabgene Lomparvovec is delivered beneath the retina. The studys assessment period begins two weeks before randomization and follows participants for up to five years. During the study, participants will attend monthly visits at a hospital or clinic where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate treatment effects. Researchers will track the annual rate of anti-VEGF injections and monitor adverse events over five years, along with changes in visual acuity. The study is designed to assess long-term treatment burden, safety, and preservation of vision in a real-world context.

Age: 50Years +All GendersPhase 3
138 locations